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INTRODUCTION:  Pancreatic  manifestations  in Von  Hippel–Lindau  (VHL)  disease  can  present  as  a  multitude
of forms,  and  their  management  can  be challenging.
PRESENTATION  OF  THE  CASE:  A  66-year-old  woman  presented  with  increasing  abdominal  girth without
other  associated  symptoms  of  nausea,  vomiting,  abdominal  pain,  weight-loss,  and  jaundice.  Her  medical
and  surgical  histories  were  signiﬁcant  for type  II diabetes,  cerebral  tumor  resection,  bilateral  nephrec-
tomies,  and  laser  photocoagulation  of  retinal  hemangiomas.  Computed  tomography  (CT)  of  the abdomen





DISCUSSION:  The  ﬁndings  on  the  subsequent  cross-sectional  MRI  imaging  signiﬁed  pancreatic  manifes-
tations  in  VHL  disease.
CONCLUSION:  The  management  of  VHL  disease-associated  benign  pancreatic  cystic lesions  involves  inter-
val monitoring  with  cross-sectional  imaging  for  malignant  changes/development.
© 2016  The  Authors.  Published  by  Elsevier  Ltd.  on behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
Von Hippel–Lindau (VHL) disease is a rare autosomal domi-
antly inherited familial syndrome with an incidence of 2–3 cases
er 100,000 population [1]. Approximately 65–75% of patients with
HL as a component of multi-visceral tumors have some form of
ancreatic lesions (cystic and solid tumors) [2]. The incidence of
ancreatic lesions among the VHL population varies considerably
mong different kindred. An incidence rate of 37% in Hawaiian VHL
indred was reported compared with 0% in Newfoundland VHL
indred [1]. The pancreatic lesions can be benign or malignant,
an produce symptoms due to the mass effect or hormonal activ-
ty, can present as recurrent multifocal lesions, or be associated
ith lesions involving several organs simultaneously. Thus, it is of
aramount importance to understand the management of various
ancreatic manifestations of VHL.
. Case report
A 66-year old woman presented for the evaluation of increasing
bdominal girth with no other associated symptoms of abdominal
ain, weight-loss, and jaundice. We  report her case in line with
ARE criteria [3]. Her medical and surgical histories included type
I diabetes mellitus, dyslipidemia, osteoporosis, cerebral tumor
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resection in 1976 and 1981, laser photocoagulation of retinal
hemangiomas, bilateral nephrectomies in 1998 for renal cell carci-
noma, and a living unrelated renal transplant in 2000. Her family
history was  signiﬁcant for paternal demise from renal cell carci-
noma and two  other family members who had cerebral tumors
resected. Abdominal examination was signiﬁcant for distension
with a non-tender abdominal mass most profoundly palpable in the
epigastrium. Magnetic resonance imaging of the abdomen showed
major replacement of the pancreas with a multiloculated cystic
lesion (Fig. 1). Imaging ﬁndings showed the disease to be exten-
sive, with a multitude of pancreatic cystic lesions—simple cysts,
serous cystadenomas without cystic characteristics concerning car-
cinoma, or the presence of solid tumors. The tumor markers CA
19-9 and chromogranin A were within the normal range. Hence,
monitoring with serial cross-sectional imaging studies was recom-
mended for this patient for changes in the cystic characteristics
concerning carcinoma or the development of solid lesions. Since
the diagnosis, patient has been followed up at our hepatobiliary
pancreatic center every six months with cross-sectional imagining
for any changes in the existing lesions and for development of any
further new lesions.
3. Discussion
Described independently in 1911 by Hippel and in 1926 by
Lindau [4], VHL disease is a rare autosomal dominantly inherited
multisystem disease that is characterized by neoplastic lesions of
the central nervous system (CNS) and various visceral organs due
to loss of the VHL tumor suppression gene on the short arm of chro-
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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pFig. 1. Magnetic resonance imaging of abdomen (panel A–D). Arrow head: multipl
osome 3. The prevalence of VHL disease has been reported to be
 in 1,000,000 families [5]. Patients with VHL disease are found to
ave retinal angiomas, renal cell carcinomas, pheochromocytomas,
NS hemangioblastomas, tumors of the inner ear and epididymis,
ystic lesions of the ovaries, and cystic and endocrine tumors of the
ancreas. The clinical diagnostic criteria, as proposed in 1964 by
elmon and Rosen for VHL disease, are as follows: (i) greater than
ne CNS hemangioblastoma; (ii) CNS hemangioblastoma in com-
ination with visceral manifestation of VHL disease; and (iii) any
anifestation and a known family history of VHL disease [6].
Approximately 7.6% of patients with VHL disease might present
ith pancreatic manifestations alone. The manifestations of pan-
reatic lesions in VHL disease can present as a cystic and/or solid
esion. Combined lesions are reported in 11.5% of patients with VHL
isease [7]. The solid lesions are most often neuroendocrine tumors,
nd the cystic lesions are most often simple cysts and serous cys-
adenomas [5], as presented in this case.Pancreatic neuroendocrine tumors (pNETs) are found in 5–17%
f VHL disease patients [8]. Often of islet cell tumor origin and
ften found in women (66%) at a median age of 38 years, 17–25% of
NETs have metastasized at the time of diagnosis [9]. On the otherreatic cysts; single arrow: benign simple cysts; oval arrow: serous cystadenomas.
hand, most cystic manifestations of VHL disease are benign, but
differentiation of these lesions from premalignant cystic lesions,
such as intraductal papillary mucinous neoplasms or mucinous cys-
tadenomas is mandatory. Because renal cell carcinoma is one of
the components of VHL disease, metastatic lesions to the pancreas
should also be considered in the differential diagnosis [4].
Most of the pancreatic lesions in VHL disease are asymptomatic.
When symptomatic, they often present with vague symptoms of
epigastric pain, diarrhea [9], dyspepsia [7], and obstructive jaun-
dice. Most often, these patients present initially with neurological
symptoms associated with VHL disease due to involvement of
the CNS [10] rather than symptoms associated with pancreas
involvement. This case highlights the importance of evaluating
VHL patients for abdominal pathology despite most patients being
asymptomatic.
Imaging is of paramount importance as a tool to identify
and differentiate benign lesions from malignant tumors, and
for any transformation of lesions from baseline characteristics.
MRI  is the preferred imaging study for the absence of radiation
and with respect to the current literature recommendation for
annual surveillance of the abdominal manifestation. Characteris-
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ic MRI  ﬁndings differ depending on the lesion. Pancreatic cysts
ppear hypointense on T1-weighted images and hyperintense on
2-weighted images without enhancement on post-gadolinium
mages. Pancreatic microcystic serous cystadenomas appear as
ircumscribed encapsulated masses, hypointense on T1-weighted
mages and hyperintense on T2-weighted images, with radial septa
nd a peripheral wall that enhance in post-gadolinium images,
nd with a central ﬁbrous scar. Macrocystic serous cystadenomas
ppear as ﬂuid ﬁlled lesions with the septa and peripheral wall that
o not enhance in the post-gadolinium images. Neuroendocrine
umors show intense and early enhancement in post-gadolinium
mages [11].
The management of pancreatic lesions is dependent on the
ymptomology and ﬁndings on cross-sectional imaging. Although
ost patients present with no pancreatic symptoms, the pancre-
tic lesions should be assessed prior to any surgical intervention
hat a patient might undergo due to associated neoplasms of other
isceral structures. The treatment strategy for the management of
ancreatic lesions can be challenging, because they might present
s multiple lesions or develop recurrent lesions that might jeop-
rdize the functional adequacy of the remnant pancreas. Most
euroendocrine tumors are hormonally non-functional but require
esection due to the metastatic risk to distant organs (11–20%) or
ocal invasiveness [2]. Current recommendations for the treatment
f pNETs in VHL disease is based on the prognostic factors of tumor
ize (≥3 cm), mutation in exon 3, and the tumor doubling time
≤500 d). Having two or three of these criteria requires surgical
esection, while having one or no criteria involves monitoring by
ross-sectional imaging (CT/MRI) every 6–12 months or 2–3 years,
espectively [12]. Most cystic lesions are asymptomatic, but might
ause endocrine and/or exocrine insufﬁciency and need to be dif-
erentiated from lesions with a malignant potential or those that
re malignant. Lesions that are malignant or suspicious of malig-
ancy, or those that cannot be distinguished from benign lesions or
ausing symptoms due to compression on adjacent organs, require
perative resection [5]. Intervention might be warranted if these
esions cause compression on the intestine or bile duct
. Conclusion
VHL disease is a familial disease characterized by neoplasms of
arious visceral organs including pancreas. The pancreatic mani-
estation of VHL disease can present as a cystic, solid, or combined
esion. The management is complex because of the challenge in
he differentiation of benign cystic lesions from malignant lesions,
otential for malignant transformation, and development of solid
esions. The treatment strategy can be complex because of its mul-
ifocal presentation and recurrence of the pathology threatening
he functional adequacy of the remnant pancreas. Cross-sectional
onitoring of benign lesions, and resection of solid or malignant
esions or lesions with a mass effect, is recommended.onﬂicts of interest
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